JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB131612

Goat Anti-Human IgG Fc (SureLight® PE)

Be the first to review this product! Submit a review

|

(2 Publications)

Suitable for FuncS, Flow Cyt. Cited in 2 publications.

View Alternative Names

Immunoglobulin heavy constant gamma 1, Ig gamma-1 chain C region, Ig gamma-1 chain C region EU, Ig gamma-1 chain C region KOL, Ig gamma-1 chain C region NIE, IGHG1

Key facts

Host species

Goat

Target species

Human

Target isotype

IgG

Target specificity

Fc region

Minimal cross-reactivity
Pre-adsorbed

No

Conjugation

SureLight® PE

Excitation/Emission
Applications

FuncS, Flow Cyt

applications

Clonality

Polyclonal

Isotype

IgG

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "FuncS": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "Flow Cyt": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Properties and storage information

Form
Lyophilized
Reconstitution
Reconstitute in 1 mL of water
Storage buffer
pH: 7.4 Preservative: 0.05% Sodium azide Constituents: 1.712% Sucrose, 1.4% Sodium phosphate, 0.88% Sodium chloride, 0.1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C

Product protocols

Target data

Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed : 20176268, PubMed : 22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed : 17576170, PubMed : 20176268). Mediates IgG effector functions on monocytes triggering ADCC of virus-infected cells.
See full target information IGHG1

Additional targets

IGHG2,IGHG3,IGHG4

Publications (2)

Recent publications for all applications. Explore the full list and refine your search

Advanced science (Weinheim, Baden-Wurttemberg, Germany) 11:e2310204 PubMed38937984

2024

High-Affinity Superantigen-Based Trifunctional Immune Cell Engager Synergizes NK and T Cell Activation for Tumor Suppression.

Applications

Unspecified application

Species

Unspecified reactive species

Yao-An Yu,Wan-Ju Lien,Wen-Ching Lin,Yi-Chung Pan,Sin-Wei Huang,Chung-Yuan Mou,Che-Ming Jack Hu,Kurt Yun Mou

The British journal of dermatology 182:648-657 PubMed31090221

2019

T helper 22 cells from Han Chinese patients with atopic dermatitis exhibit high expression of inducible T-cell costimulator.

Applications

Unspecified application

Species

Unspecified reactive species

Q Jiao,Q Qian,C Liu,Y Luo,F Fang,M Wang,J Ji,H Qian,X Zhang,M Maurer
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com